Rising Rates of Teenage E-cigarette Use in the US

Oct.20.2022
Rising Rates of Teenage E-cigarette Use in the US
Teenage e-cigarette use rises in the US, with 14.1% of high school students and 3.3% of middle school students using them. Experts warn of health risks.

The proportion of teenagers using e-cigarettes has increased once again, according to a report released by the US Centers for Disease Control and Prevention. The National Youth Tobacco Survey, led by the US Food and Drug Administration and the CDC, showed that 14.1% of high school students and 3.3% of middle school students reported using e-cigarettes or other vaping products in the recent past. These figures suggest that approximately 2.5 million middle and high school students in the US are now vaping. Experts are particularly concerned that over a quarter of students are using e-cigarettes on a daily basis.


Dr. Ramiro Fernandez, Assistant Professor at the Division of Thoracic Surgery under Dr. David J. Sugarbaker at the Michael E. DeBakey College of Medicine, states that while extensive long-term data on the effects of electronic cigarettes are lacking, we are aware of acute lung injuries associated with their use, known as EVALI or electronic cigarette-associated lung injury.


Patients with EVALI experience respiratory symptoms and signs, including shortness of breath and decreased oxygen levels. They may also develop severe diffuse inflammation in their lungs, which can lead to death," said Fernandez. As of February 2020, there have been 2,807 reported cases of hospitalization or death due to EVALI, with 68 confirmed deaths.


Most e-cigarettes contain nicotine. In fact, a study by the Centers for Disease Control and Prevention found that 99% of e-cigarettes sold in assessment locations in the US contained nicotine. Nicotine can harm the developing brains of adolescents, which do not fully mature until around age 25. Additionally, research shows that teenagers who use e-cigarettes are more likely to start smoking traditional cigarettes in the future.


Electronic cigarettes also contain other harmful substances, such as ultrafine particles that can be inhaled deep into the lungs, flavorings associated with serious lung diseases, heavy metals like nickel, tin, and lead, as well as other carcinogens.


According to the American Cancer Society, the aerosol in e-cigarettes contains addictive substances that can lead to lung disease, heart disease, and cancer. A study by Johns Hopkins University in October 2021 on the components of e-cigarettes shows that there are thousands of chemical components in e-cigarette products, many of which have not been identified. The research team identified a pesticide, three chemicals never before found in e-cigarettes, and two flavorings associated with respiratory irritation and potential toxicity.


Although some people believe that electronic cigarettes can help people quit smoking, they have not been approved by the Food and Drug Administration as an aid. To quit smoking, seek help from your doctor or other support services, such as the smoking cessation program at the Baylor College of Medicine's Chest Clinic. It is important to note that electronic cigarettes are harmful not only to young people but also to adults.


People need to know that electronic cigarettes are harmful to your health," Dr. Fernandez stated. "Although the long-term effects are still unclear, data shows noticeable risks to cardiovascular and lung health.


For more information and resources, please see Baylor College of Medicine's position paper on taking action to address the issue of youth smoking and vaping.


Author: Tiffany Harston, Assistant to the Michael E. DeBakey Surgical Communications at Baylor College of Medicine.


Statement:


This article is compiled from third-party information and is intended for industry professionals for informational and educational purposes only.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for internal industry exchange and research purposes.


Due to the limitations of the compiler's skills, the translated article may not express the same meaning as the original. Please refer to the original article for accuracy.


In regards to any domestic, Hong Kong/Macau/Taiwan-related, or foreign statements and positions, 2FIRSTS is fully aligned with the Chinese government.


The copyright of compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06